Some of you are extremely short sighted. Go on to the Orbimed...

Some of you are extremely short sighted.  Go on to the Orbimed website.  have a look at their news stream.  A company Orbimed have in their portfolio, Cardioxyl was acquired by Bristol Myers Squibb for $300 Million upfront with $1.78 Billion in Milestone payments.  Granted, Cardioxyl is not a cancer treatment, but this deal gives an example of some of the transactions Orbimed have been involved with.  Take a chill pill and watch this unfold.  

"Bristol-Myers Squibb will pay $300 million in cash and up to $1.78 billion in milestone payments to acquire North Carolina-based Cardioxyl Pharmaceuticals. The 10-year-old firm is developing small-molecule drugs for cardiovascular diseases based on scientific work originating at Johns Hopkins University. Cardioxyl’s lead candidate, CXL-1427, is a nitroxyl donor in Phase II clinical development for heart failure. According to BMS, the drug doesn’t just treat symptoms but potentially could change the course of the disease ."